Stay updated on Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial page.

Latest updates to the Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange Detected- The page revision label was updated to v3.5.4, replacing the previous v3.5.3 and signaling a minor update to the page without changing its study details.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page revision was updated from v3.5.2 to v3.5.3, representing a new version of the study record. This change signals a minor update to the page's versioning without altering the substantive study information.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision: v3.5.2 was added and Revision: v3.5.0 was removed, updating the page's version metadata without changes to the core study details.SummaryDifference0.1%

- Check70 days agoChange DetectedVersion updated from v3.4.3 to v3.5.0 on the page, indicating a platform-level update without changes to study data or content.SummaryDifference0.1%

- Check77 days agoChange DetectedRevision: v3.4.3 was added, replacing the previous v3.4.2 in the revision history.SummaryDifference0.1%

- Check99 days agoChange DetectedResults section updated with data on dose-limiting toxicities, timing, and RECIST responses. Exploratory biomarker endpoints were removed.SummaryDifference3%

Stay in the know with updates to Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial page.